Agios Pharmaceuticals Stock On the Move After Today's News

By Bobby Samwell • Monday, January 08 16:42 • Permanent Link

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) has announced its anticipated milestones and value-driving catalysts through 2026 at the 42nd annual J.P. Morgan Healthcare Conference. The company's stock moved 5.7% and is currently trading at $24.45 per share.

Brian Goff, Chief Executive Officer at Agios, expressed optimism about the company's future, stating, "This robust series of near-term catalysts positions Agios for potential launches of a first- and best-in-class therapy in thalassemia in 2025 and in sickle cell disease in 2026, and we look forward to maximizing the commercial opportunities ahead of us. Supported by our strong cash position, Agios is poised for significant progress in the next 12-24 months, and we look forward to the opportunity to deliver a novel oral treatment option for two additional hematologic diseases with high unmet need."

The company highlighted several key achievements in 2023, including positive data from the phase 3 study of its lead pyruvate kinase (PK) activator, mitapivat, in non-transfusion-dependent alpha- or beta-thalassemia. Additionally, Agios completed enrollment in various phase 3 studies across its PK activator franchise and announced clinical proof-of-concept in a phase 2a study, among other milestones.

Looking ahead, Agios outlined its anticipated 2024 milestones, including completing enrollment in the phase 3 portion of the rise up study of mitapivat in sickle cell disease and reporting topline data from the phase 3 energize-t study of mitapivat in transfusion-dependent thalassemia, among others.

Moreover, Agios expects four additional phase 3 readouts by the end of 2025, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026. The company also anticipates potential FDA approvals for mitapivat in pediatric PK deficiency by 2026.

Agios Pharmaceuticals is a pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class PK activator for adults with PK deficiency and is advancing a robust clinical pipeline of investigational medicines with programs in various rare hematologic diseases.

The company's full 8-K submission is available here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.